Cargando…

PTEN loss is not a determinant of time to castration-resistance following androgen-deprivation therapy in prostate cancer: a study from Jordan

Androgen deprivation therapy (ADT) remains the principal treatment of advanced prostate cancer. However, most patients eventually experience treatment failure, resulting in castrate-resistant prostate cancer (CRPC). Loss of the tumor suppressor gene phosphatase and tensin homolog (PTEN) has been lin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alzoubi, Abdallah, Al Bashir, Samir, Smairat, Aya, Alrawashdeh, Ahmad, Haddad, Husam, Kheirallah, Khalid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Carol Davila University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251393/ https://www.ncbi.nlm.nih.gov/pubmed/37305830 http://dx.doi.org/10.25122/jml-2023-0034

Ejemplares similares

Medical, Dental, and Nursing Students’ Experience with Virtual Practical Sessions: A Cross-Sectional Study in a Developing Country
por: Al Bashir, Samir, et al.
Publicado: (2023)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions
por: Joshi, Molishree, et al.
Publicado: (2019)

Androgen deprivation-induced OPHN1 amplification promotes castration-resistant prostate cancer
por: Liu, Junjiang, et al.
Publicado: (2022)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
por: Kim, Yejin, et al.
Publicado: (2016)

The Effect of Strict State Measures on the Epidemiologic Curve of COVID-19 Infection in the Context of a Developing Country: A Simulation from Jordan
por: Kheirallah, Khalid A., et al.
Publicado: (2020)

Jordan’s Pandemic Influenza Preparedness (PIP): A Reflection on COVID-19 Response
por: Kheirallah, Khalid A., et al.
Publicado: (2022)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
por: Caramella, Irene, et al.
Publicado: (2022)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Jang, Ho Seong, et al.
Publicado: (2016)

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
por: Punnoose, Elizabeth A, et al.
Publicado: (2015)

Neurological Assessment and Nerve Conduction Study Findings in 22 Patients with Alkaptonuria from Jordan
por: Alrawashdeh, Omar, et al.
Publicado: (2017)

How do we define “castration” in men on androgen deprivation therapy?
por: Itty, Sarin, et al.
Publicado: (2020)

Domestic violence against women in Jordan: analysis of the demographic and health survey dataset 2017-2018
por: Kheirallah, Khalid Ahmed, et al.
Publicado: (2023)

Weight Loss for Obese Prostate Cancer Patients on Androgen Deprivation Therapy
por: WILSON, REBEKAH L., et al.
Publicado: (2021)

Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
por: Merseburger, Axel S., et al.
Publicado: (2014)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
por: Min, Kyungchan, et al.
Publicado: (2020)

Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?
por: Niklas, Christina, et al.
Publicado: (2021)

A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer
por: Zhang, Jingsong, et al.
Publicado: (2022)

A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss
por: Myint, Zin W., et al.
Publicado: (2021)

Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy
por: Kang, Minyong, et al.
Publicado: (2015)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

A Comparative Piloting of Determinants of Self-Medication Among University Students in the MENA Region; UAE and Jordan as an Example
por: Alzoubi, Abdallah, et al.
Publicado: (2023)

Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer
por: Hah, Yoon Soo, et al.
Publicado: (2019)

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2018)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss
por: Chen, Yu, et al.
Publicado: (2013)

Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
por: Kim, Ki Bom, et al.
Publicado: (2015)

Hypercholesterolemia Is Associated with a Shorter Time to Castration-Resistant Prostate Cancer in Patients Who Have Undergone Androgen Deprivation Therapy
por: Jeon, Jong Chul, et al.
Publicado: (2016)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Androgen Deprivation Leads to Increased Carbohydrate Metabolism and Hexokinase 2 Mediated Survival in Pten/Tp53 Deficient Prostate Cancer
por: Martin, Philip L., et al.
Publicado: (2016)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Loss of SNAI2 in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy
por: Cmero, Marek, et al.
Publicado: (2021)

Complete androgen blockade vs. medical castration alone as adjuvant androgen deprivation therapy for prostate cancer patients following radical prostatectomy: a retrospective cohort study
por: Jin, Di, et al.
Publicado: (2022)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3g3grjh64oe1vh44n9o84varan